Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis

CONCLUSION: In 15 out of 22 cases, the company either disagreed with the decision to withdraw the drug or felt that the drug should continue to be available to Canadian patients.PMID:34057099 | DOI:10.3233/JRS-210013
Source: International Journal of Risk and Safety in Medicine - Category: Drugs & Pharmacology Authors: Source Type: research